Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD8-targeted lipid nanoparticle delivering CD20 CAR mRNA
- Development stage
- Preclinical
- Lead developer
- Mirai Bio
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CD8-targeted lipid nanoparticle delivering CD20 CAR mRNA is an investigational in vivo CAR-T cell therapy. It utilizes targeted lipid nanoparticles (tLNPs) decorated with anti-CD8 binders to selectively deliver mRNA encoding a CD20-directed chimeric antigen receptor (CAR) to endogenous CD8+ T cells. Once the mRNA is translated, the recipient T cells express the CAR and can target and deplete CD20-expressing B cells. This approach aims to provide the efficacy of CAR-T therapy without the need for complex and costly ex vivo cell manufacturing. It is being developed for B-cell malignancies and B-cell-mediated autoimmune diseases such as lupus and myositis.
- Other names
- CD8-targeted lipid nanoparticle delivering CD20 CAR mRNACD-8-targeted lipid nanoparticle delivering CD20 CAR mRNACD 8-targeted lipid nanoparticle delivering CD20 CAR mRNA
02
Targets
CD8A (CD8 alpha/beta Coreceptor)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on CD8-targeted lipid nanoparticle delivering CD20 CAR mRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD8-targeted lipid nanoparticle delivering CD20 CAR mRNA.